Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A redox system for brain targeted estrogen delivery causes chronic body weight decrease in rats.

K S Estes1, M E Brewster, N S Bodor

  • 1Center for Drug Design and Delivery, College of Pharmacy, University of Florida, Gainesville 32610.

Life Sciences
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Downstream processing of polymer-based amorphous solid dispersions to generate tablet formulations.

International journal of pharmaceutics·2015
Same author

Improved Delivery Through Biological Membranes. XXIV. Synthesis, in Vitro Studies, and in Vivo Characterization of Brain-Specific and Sustained Progestin Delivery Systems.

Pharmaceutical research·2013
Same author

Brain-targeted delivery of estrogens.

Reviews in the neurosciences·2011
Same author

Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin.

European journal of medical research·2010
Same author

Monoglyceride-based self-assembling copolymers as carriers for poorly water-soluble drugs.

International journal of pharmaceutics·2009
Same author

Usefulness of a novel Caco-2 cell perfusion system II. Characterization of monolayer properties and peptidase activity.

Die Pharmazie·2009
Same journal

Corrigendum to "Adipose stem cells-derived microvesicles and chicken egg-derived exosomes attenuate cardiac ischemia/reperfusion injury through AKT/ERK/Nrf2/HO-1 axis to inhibit apoptosis and inflammation and restore autophagy" [Life Sci. 395 (2026) 124364].

Life sciences·2026
Same journal

MAGED1 stabilizes NEUROD1 to promote Per3 expression in the pineal gland.

Life sciences·2026
Same journal

TNF-centered network pharmacology and molecular modeling of selected Andrographis paniculata compounds in hypertension.

Life sciences·2026
Same journal

Retraction notice to "Beneficial effect of Calculus Bovis Sativus on 17α-ethynylestradiol-induced cholestasis in the rat" [Life Sci. 113 (2014) 22-30].

Life sciences·2026
Same journal

Soluble PD-1 drives renal fibrosis in CKD by disrupting immune homeostasis: Therapeutic mitigation via a targeted sPD-1 sequestration strategy.

Life sciences·2026
Same journal

METTL1 promotes hepatic steatosis by mediating m<sup>7</sup>G modification of ALOX15B mRNA.

Life sciences·2026
See all related articles

Estradiol carriers (CDS-E2) significantly reduced weight gain in rats, demonstrating potent and sustained effects. These estrogen-specific compounds were more effective than traditional estradiol treatments.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Neuroscience

Background:

  • Estradiol plays a role in regulating body weight.
  • Developing targeted drug delivery systems can enhance therapeutic efficacy.
  • Brain-directed delivery of hormones offers novel treatment avenues.

Purpose of the Study:

  • To investigate the effects of novel redox-based carriers delivering estradiol (CDS-E2) and ethinyl estradiol (CDS-EE) on body weight in rats.
  • To compare the potency and duration of action of CDS-E2 and CDS-EE on weight gain and luteinizing hormone (LH) suppression.
  • To determine if the observed effects are estrogen-specific.

Main Methods:

  • Administration of CDS-E2 and CDS-EE to castrate and ovariectomized (OVX) rats.
  • Dose-response studies comparing weight gain and LH suppression.

Related Experiment Videos

  • Comparison with equimolar doses of estradiol and estradiol valerate.
  • Testing carrier-linked testosterone in intact rats.

    • Main Results:

    • A single dose of CDS-E2 (3 mg/kg) decreased weight gain in castrate rats for at least 24 days.
    • Weight reduction was detected at lower doses and lasted longer than LH suppression in OVX rats.
    • CDS-E2 and CDS-EE were more potent in reducing weight gain than estradiol or estradiol valerate.
    • Intact rats showed decreased weight gain but were less sensitive to CDS-E2 than OVX rats.
    • Carrier-linked testosterone did not affect weight.

    Conclusions:

    • Redox-based carriers enable potent and sustained reduction in body weight mediated by estradiol.
    • The weight-reducing effects are estrogen-specific and more pronounced in OVX rats.
    • These novel delivery systems offer a promising approach for managing body weight through targeted estrogenic action.